Compare ACRE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | SLN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 300.9M |
| IPO Year | 2011 | N/A |
| Metric | ACRE | SLN |
|---|---|---|
| Price | $4.88 | $11.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.38 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 512.9K | 497.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $4.19 |
| 52 Week High | $5.89 | $12.31 |
| Indicator | ACRE | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 60.88 |
| Support Level | $4.67 | $5.87 |
| Resistance Level | $5.06 | $12.19 |
| Average True Range (ATR) | 0.14 | 0.90 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 81.43 | 76.85 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.